ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets.
about
Melanoma: from melanocyte to genetic alterations and clinical optionsMelanoma Cancer Stem Cells: Markers and FunctionsAldehyde dehydrogenase 1A1 in stem cells and cancerAldehyde dehydrogenase as a marker and functional mediator of metastasis in solid tumorsMolecular biomarkers of cancer stem/progenitor cells associated with progression, metastases, and treatment resistance of aggressive cancersStem cells and targeted approaches to melanoma cureCatecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disordersA synthetic modular approach for modeling the role of the 3D microenvironment in tumor progressionAlternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem CellsCrystal structure of human aldehyde dehydrogenase 1A3 complexed with NAD(+) and retinoic acidKDM4C, a H3K9me3 Histone Demethylase, is Involved in the Maintenance of Human ESCC-Initiating Cells by Epigenetically Enhancing SOX2 ExpressionTopical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases.Proteomic Upregulation of Fatty Acid Synthase and Fatty Acid Binding Protein 5 and Identification of Cancer- and Race-Specific Pathway Associations in Human Prostate Cancer Tissues.Arsenic trioxide induces differentiation of CD133+ hepatocellular carcinoma cells and prolongs posthepatectomy survival by targeting GLI1 expression in a mouse modelThe soy-derived peptide Lunasin inhibits invasive potential of melanoma initiating cellsALDH1A1 expression correlates with clinicopathologic features and poor prognosis of breast cancer patients: a systematic review and meta-analysisAldehyde dehydrogenases: from eye crystallins to metabolic disease and cancer stem cellsSOX2 regulates self-renewal and tumorigenicity of human melanoma-initiating cells.Prognostic value of cancer stem cell marker aldehyde dehydrogenase in ovarian cancer: a meta-analysisNEK2 mediates ALDH1A1-dependent drug resistance in multiple myelomaPhenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell linesALDH maintains the stemness of lung adenoma stem cells by suppressing the Notch/CDK2/CCNE pathway.NOTCH-induced aldehyde dehydrogenase 1A1 deacetylation promotes breast cancer stem cells.Gene expression profiling identifies microphthalmia-associated transcription factor (MITF) and Dickkopf-1 (DKK1) as regulators of microenvironment-driven alterations in melanoma phenotypeCancer stem cells as a target population for drug discovery.Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.Coating Solid Lipid Nanoparticles with Hyaluronic Acid Enhances Antitumor Activity against Melanoma Stem-like Cells.Cancer stem cell vaccine inhibits metastases of primary tumors and induces humoral immune responses against cancer stem cellsMiR-187 Targets the Androgen-Regulated Gene ALDH1A3 in Prostate Cancer.Essential role of aldehyde dehydrogenase 1A3 for the maintenance of non-small cell lung cancer stem cells is associated with the STAT3 pathway.A STAT3-NFkB/DDIT3/CEBPβ axis modulates ALDH1A3 expression in chemoresistant cell subpopulations.ALDH1A3: A Marker of Mesenchymal Phenotype in Gliomas Associated with Cell InvasionALDH3A1 Plays a Functional Role in Maintenance of Corneal Epithelial HomeostasisSurvival of skin cancer stem cells requires the Ezh2 polycomb group protein.Iterative sorting reveals CD133+ and CD133- melanoma cells as phenotypically distinct populations.Redox effects and cytotoxic profiles of MJ25 and auranofin towards malignant melanoma cells.Aldehyde dehydrogenase activity plays a Key role in the aggressive phenotype of neuroblastoma.Understanding melanoma stem cellsTFAP2 paralogs regulate melanocyte differentiation in parallel with MITF.Cancer stem cells and tumor transdifferentiation: implications for novel therapeutic strategies.
P2860
Q21284811-D649908C-C70A-46E3-85D4-F9CE5C25ABABQ26765435-4131941F-8BB0-4268-99E2-EDBE4E1C7244Q26771185-561A6C4C-469E-48C0-B0D2-1469F0ED442CQ26786476-6D590B9D-8CB4-4D23-82BA-CE66BCC5347BQ26822406-E7D71EA5-1C32-4BCA-9059-D0765ECA74A0Q26825014-97762909-F8CF-4C33-B539-AB7EDD6B5B6FQ26826093-4EE2FE1F-8520-45C6-A44B-2C9D72799ED7Q27304351-65EB150C-AB9D-4C88-88F6-0658BBDDC98CQ28084243-7CFC0411-ABC6-4E7F-9C6D-9F99466DEB16Q28115266-C9DA7D9E-4769-459C-8360-9B5E9C00940BQ28829171-EC3BC174-665D-409E-A106-0B4A6ADF670FQ30276126-6CC39560-DDC3-4DCA-8DCD-2B2D5A5B0F77Q30357469-95278EEE-19A2-421E-BCD4-B9D10CD83D63Q33616264-D0C91830-9B54-4BB9-96F7-E31444C67E1BQ33648931-5FCD08C8-AC74-43FE-AE74-D9F4DA0E8DE5Q33804523-5C52D966-A8D6-44AD-A92F-EB1A0FC3B465Q34026132-DC5025D6-27B8-4545-B49F-DE7089857432Q34269756-5679451C-C75B-457C-A42D-C80A7777F769Q35055205-96F2080F-DC07-4AC9-A703-605E51576C5CQ35067960-7F13A5DC-F209-4C00-BCBC-EE9619781ED6Q35128148-87D3BDA9-30A0-4965-8754-3DD112639606Q35132170-DA7DE7BF-F420-4358-BA31-7875345AACF2Q35145324-6DE16E8B-1B6C-45A4-A21D-080EC55CA94DQ35147858-3F179E61-B699-41A3-A7E2-9A65A8D88593Q35390334-69ED1675-A3F4-4965-A129-2903BFACB1A7Q35412202-BA74A002-BD26-4C69-BB34-7733935C8AE8Q35476018-4B0683B6-834D-436F-8053-7396C24D232DQ35507539-0BE58E18-89FF-463C-B8B1-D5063D814E82Q35602182-A8332DDA-EDC6-45AA-9F68-53DE53960F01Q35627749-8EEC4490-F1FB-437E-BECB-BF7A40D66C57Q35828644-475D7727-8C77-4EAD-AD1C-F65E9902DC0EQ35843516-AADDE1E8-2C3B-4A56-9B70-7B20A38D4954Q35890126-12E9F41E-564A-4E84-99F1-2914FC73F9C5Q36087138-C2C021FF-AC9E-4521-B739-F0A53525F3E1Q36129189-1738B612-F436-43F7-BD89-D132643B96EDQ36140846-A9F85B0C-3AD7-49F0-955B-5BFA792CA000Q36159646-A77EE9A2-C30D-4658-B5AE-2F7141B09EB4Q36292299-BFEF748F-DDA0-4C42-852E-FEC42B6BBD46Q36294018-6BEE285A-39A8-45D2-9438-BA6DBE523BA7Q36796375-9AF23281-4DFD-4B78-9E61-475746A712E0
P2860
ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
ALDH1A isozymes are markers of ...... potential therapeutic targets.
@ast
ALDH1A isozymes are markers of ...... potential therapeutic targets.
@en
type
label
ALDH1A isozymes are markers of ...... potential therapeutic targets.
@ast
ALDH1A isozymes are markers of ...... potential therapeutic targets.
@en
prefLabel
ALDH1A isozymes are markers of ...... potential therapeutic targets.
@ast
ALDH1A isozymes are markers of ...... potential therapeutic targets.
@en
P2093
P2860
P356
P1433
P1476
ALDH1A isozymes are markers of ...... potential therapeutic targets
@en
P2093
David A Norris
David C Thompson
Dennis R Roop
Katiuscia Dallaglio
Martin D McCarter
Mayumi Fujita
Rene Gonzalez
Steven E Robinson
William A Robinson
P2860
P304
P356
10.1002/STEM.1193
P577
2012-10-01T00:00:00Z